Udvalget for Humanmedicinske Lægemidler (CHMP) konkluderede, at fordelene ved Trizivir opvejer risiciene ved behandling af hiv- smittede voksne.
The Committee for Medicinal products for Human Use (CHMP) decided that Trizivir’ s benefits are greater than its risks for the treatment of HIV infection in adults.